KNSA (STOCKS)
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$77.830000
-0.320000 (-0.41%)
Prev close: $78.150000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sanj K. Patel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6,465.54M
- Employees
- 315
- P/E (TTM)
- 79.46
- P/B (TTM)
- 9.32
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$0.30 | $0.30 | -0.0047 | -1.54% |
|
Mar 2026 (Q1)
|
$0.27 | $0.21 | +0.0647 | +31.51% |
|
Dec 2025 (Q4)
|
$0.17 | $0.38 | -0.2119 | -55.49% |
|
Sep 2025 (Q3)
|
$0.23 | $0.33 | -0.0998 | -30.26% |
Financial Statements
| Revenues | $840.85M |
| Benefits Costs and Expenses | $726.60M |
| Cost Of Revenue | $85.57M |
| Costs And Expenses | $726.60M |
| Gross Profit | $755.28M |
| Operating Expenses | $655.03M |
| Selling, General, and Administrative Expenses | $230.90M |
| Depreciation and Amortization | $1.79M |
| Research and Development | $127.15M |
| Other Operating Expenses | $295.58M |
| Operating Income/Loss | $100.25M |
| Income/Loss From Continuing Operations After Tax | $80.66M |
| Income/Loss From Continuing Operations Before Tax | $114.25M |
| Income Tax Expense/Benefit | $33.59M |
| Income Tax Expense/Benefit, Deferred | $14.55M |
| Net Income/Loss | $80.66M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $80.66M |
| Net Income/Loss Available To Common Stockholders, Basic | $80.66M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.07 |
| Diluted Earnings Per Share | $0.98 |
| Basic Average Shares | 229,404,290 |
| Diluted Average Shares | 246,794,814 |
| Assets | $896.11M |
| Current Assets | $668.63M |
| Inventory | $70.93M |
| Other Current Assets | $597.70M |
| Noncurrent Assets | $227.48M |
| Fixed Assets | $2.58M |
| Other Non-current Assets | $224.90M |
| Liabilities | $241.96M |
| Current Liabilities | $171.25M |
| Accounts Payable | $12.40M |
| Wages | $20.29M |
| Other Current Liabilities | $138.56M |
| Noncurrent Liabilities | $70.71M |
| Equity | $654.15M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $654.15M |
| Liabilities And Equity | $896.11M |
| Net Cash Flow From Operating Activities | $184.97M |
| Net Cash Flow From Operating Activities, Continuing | $184.97M |
| Net Cash Flow From Investing Activities | -$239.07M |
| Net Cash Flow From Investing Activities, Continuing | -$239.07M |
| Net Cash Flow From Financing Activities | $37.74M |
| Net Cash Flow From Financing Activities, Continuing | $37.74M |
| Net Cash Flow | -$16.36M |
| Net Cash Flow, Continuing | -$16.36M |
| Comprehensive Income/Loss | $79.97M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $79.33M |
| Other Comprehensive Income/Loss | $43.18M |
| Other Comprehensive Income/Loss Attributable To Parent | -$1.33M |